J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.
You may also be interested in...
Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.
European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.